Among the AD and epilepsy disease groups, heterogeneous clinical variables warrant further evaluation in future studies with larger samples, as do genetic risk factors (e.g., APOE, MTOR, APP, and PSEN1). The gene discussed is MTOR; the disease is Alzheimer disease.